Today
On The Fly
Show Hide Related Items >> <<
$401.54 / -8.125 (-1.98%)
03/01/21 Zoom Video jumps 8% to $444.10 after Q4 results, FY22 guidance beat estimates 03/01/21 Lumen announces launch of Zoom Phone 02/03/21 Zoom Video announces availability of Zoom Rooms innovations 01/26/21 User reports indicate Zoom Video experiencing issues, says DownDetector 10:55 Today Target 'off to a strong start' in February, with comps up 20% 09:57 Today Target says testing new sortation center to expedite online orders 09:16 Today Target says 'our business model is working as intended' 08:52 Today Target not providing FY21 guidance 'in the face of continued uncertainty' $27.00 / +5.495 (+25.55%)
01/19/21 Perion Network trading halted, news pending 12/07/20 Perion Network jumps 8% to $8.37 after raising Q4, FY20 guidance 11/02/20 Perion Network, Microsoft renew strategic partnership for four more years 02/26/21 Novavax, Takeda finalize license agreement for COVID-19 vaccine in Japan 02/24/21 Takeda provides update on Novavax, Moderna COVID-19 vaccine candidates in Japan 02/22/21 House committee posts remarks from Pfizer, Moderna, J&J execs ahead of testimony 02/22/21 Novavax completes enrollment of PREVENT-19 Phase 3 trial 03/01/21 Merck announces voluntary withdrawal for KEYTRUDA in SCLC 03/01/21 Merck: FDA accepts gefapixant New Drug Application for review 02/25/21 Merck to acquire Pandion Therapeutics for $60 per share in cash 02/25/21 Merck, Pandion Therapeutics deal has approx. total equity value of $1.85B $73.25 / -11.56 (-13.63%)
03/01/21 Morphic Holding Inc trading resumes 03/01/21 Morphic Holding Inc trading halted, volatility trading pause 03/01/21 Morphic Holding reports interim results from Phase 1 trial of MORF-057 01/05/21 Morphic Therapeutic expands R&D collaboration with Janssen 09:29 Today Kohl's planning $200M-$300M in share repurchases in 2021 09:18 Today Kohl's plans to refresh approximately 675 stores over the next two years 09:03 Today Kohl's 'optimistic that brighter days are ahead' 08:56 Today Kohl's 'confident' in ability to expand operating margin to 7%-8% by 2023 02/28/21 Fly Intel: Top five weekend stock stories 02/28/21 CDC Advisory Committee recommends J&J single-shot COVID vaccine for adults 18+ 02/27/21 Johnson & Johnson Covid vaccine granted emergency approval from FDA 02/26/21 J&J confirms FDA panel recommends COVID-19 vaccine for EUA $35.50 / -14.76 (-29.37%)
03/01/21 FibroGen, AstraZeneca report FDA to hold AdCom meeting to review roxadustat NDA 12/22/20 FibroGen doses first patient in ZEPHYRUS-2 Phase 3 study of pamrevlumab 12/19/20 AstraZeneca updates on U.S. regulatory review of roxadustat 12/18/20 FibroGen says FDA extends review period for roxadustat NDA 03/01/21 Amyris to acquire Costa Brazil brand, terms not disclosed 02/24/21 Amyris launches Pipette clean baby care brand in Target 02/22/21 Amyris announces pre-clinical results for COVID RNA vaccine platform 02/02/21 Amyris announces results from clinical study of clean topical formulation 02/09/21 Jefferies Dollar General well-positioned to mitigate minimum wage headwind, says Jefferies 02/08/21 Fly Intel: Top five analyst upgrades 02/08/21 Stifel Target upgraded to Buy from Hold at Stifel 01/14/21 DA Davidson Target price target raised to $229 from $208 at DA Davidson 02/18/21 Morgan Stanley Kohl's price target raised to $40 from $27 at Morgan Stanley 02/05/21 Baird Kohl's price target raised to $58 from $48 at Baird 02/05/21 Deutsche Bank Kohl's price target raised to $55 from $51 at Deutsche Bank 02/03/21 Fly Intel: Top five analyst upgrades 02/10/21 BTIG Model N upgraded to Buy from Neutral at BTIG 02/01/21 SVB Leerink Moderna price target raised to $80 from $69 at SVB Leerink 02/01/21 Wells Fargo Moderna price target raised to $145 from $129 at Wells Fargo 02/01/21 BofA BofA downgrades Moderna to Underperform, sees shares priced for 'best-case' 02/25/21 SVB Leerink Pandion Therapeutics downgraded to Market Perform from Outperform at SVB Leerink 02/25/21 Morgan Stanley Pandion downgraded to Equal Weight from Overweight at Morgan Stanley 02/17/21 William Blair William Blair 'highly encouraged' by Nektar's collaborations with Merk, SFJ 01/21/21 Wedbush Scholar Rock price target raised to $66 from $47 at Wedbush $401.54 / -8.125 (-1.98%)
09:56 Today Fly Intel: Top five analyst upgrades 07:15 Today Morgan Stanley Zoom Video price target raised to $420 from $390 at Morgan Stanley 06:07 Today Piper Sandler Zoom Video upgraded to Overweight from Neutral at Piper Sandler 01/26/21 MKM Partners Fiverr downgraded to Sell from Neutral at MKM Partners $27.00 / +5.495 (+25.55%)
02/10/21 Lake Street Perion Network price target raised to $30 from $18 at Lake Street 02/10/21 Roth Capital Perion Network price target raised to $30 from $16 at Roth Capital 01/04/21 Lake Street Perion Network price target raised to $18 from $12 at Lake Street 12/31/20 Sidoti Perion Network price target raised to $14 from $12 at Sidoti 02/26/21 Fly Intel: Top five analyst initiations 02/26/21 Roth Capital Amyris initiated with a Buy at Roth Capital 01/06/21 Cowen Amyris upgraded to Outperform with $9 price target at Cowen 01/06/21 Cowen Amyris upgraded to Outperform from Market Perform at Cowen $73.25 / -11.56 (-13.63%)
03/01/21 Wells Fargo Morphic Holding price target raised to $103 from $40 at Wells Fargo 02/02/21 RBC Capital Morphic Holding price target raised to $50 from $35 at RBC Capital 10/26/20 RBC Capital Morphic Holding initiated with an Outperform at RBC Capital 08/11/20 BMO Capital Morphic Holding price target raised to $37 from $30 at BMO Capital $35.50 / -14.76 (-29.37%)
09:56 Today Fly Intel: Top five analyst downgrades 08:21 Today Jefferies FibroGen downgraded to Hold at Jefferies on increased risk for roxadustat 06:24 Today Citi FibroGen selloff on FDA panel a buying opportunity, says Citi 04:47 Today Jefferies FibroGen downgraded to Hold from Buy at Jefferies 02/23/21 B. Riley Securities B. Riley remains 'aggressive' buyer of Novavax after updated FDA guidance 02/22/21 Cantor Fitzgerald Cantor says PREVENT-19 gives Novavax potential for differentiated analyses 02/22/21 B. Riley Securities B. Riley reiterates Buy rating on Novavax as PREVENT-19 enrollment wraps up 02/18/21 B. Riley Securities Novavax price target raised to $397 from $334 at B. Riley Securities $401.54 / -8.125 (-1.98%)
03/01/21 Zoom Video sees FY22 EPS $3.59-$3.65, consensus $2.96 03/01/21 Zoom Video sees Q1 EPS 95c-97c, consensus 72c 03/01/21 Zoom Video reports Q4 EPS $1.22, consensus 79c 03/01/21 Notable companies reporting after market close 06:34 Today Target reports Q4 adjusted EPS $2.67, consensus $2.54 03/01/21 Notable companies reporting before tomorrow's open 11/18/20 Target reports Q3 total revenue $22.63B, consensus $20.93B $27.00 / +5.495 (+25.55%)
06:04 Today Perion Network raises FY21 revenue view to $370M-$380M from $350-$370 02/09/21 Perion Network sees FY21 revenue $350M-$370M, consensus $353.3M 02/09/21 Perion Network reports Q4 adjusted EPS 45c, consensus 18c 01/19/21 Perion Network sees Q4 EPS 35c-36, consensus 23c 03/01/21 Novavax reports Q4 EPS ($2.70), consensus ($1.49) 11/09/20 Novavax reports Q3 EPS ($3.21), may not compare to consensus $1.73 02/04/21 Merck sees FY21 adjusted EPS $6.48-$6.68, consensus $6.41 02/04/21 Merck reports Q4 adjusted EPS $1.32, consensus $1.38 02/03/21 Notable companies reporting before tomorrow's open $73.25 / -11.56 (-13.63%)
03/01/21 Morphic Holding reports 2020 EPS ($1.47), consensus ($1.41) 11/09/20 Morphic Holding reports Q3 EPS 17c, consensus (48c) 07:09 Today Kohl's sees FY21 EPS $2.45-$2.95, consensus ($2.43) 02/04/21 Kohl's reports preliminary Q4 EPS $1.00-$1.05, consensus 70c 01/26/21 Johnson & Johnson sees FY21 adjusted operational EPS $9.25-$9.45 01/26/21 Johnson & Johnson reports Q4 adjusted EPS $1.86, consensus $1.82 01/25/21 Notable companies reporting before tomorrow's open $35.50 / -14.76 (-29.37%)
03/01/21 FibroGen reports Q4 EPS (64c), consensus (24c) 11/05/20 FibroGen reports Q3 EPS 35c, consensus (80c) 08:34 Today Amyris sees FY21 revenue $400M, consensus $231.77M 08:32 Today Amyris reports Q4 adjusted EPS (3c), consensus (9c)
Hot Stocks
Show Hide Related Items >> <<
WBA Walgreens Boots Alliance 02/24/21 Walgreens says Pixel by Labcorp COVID-19 PCR test to be available OTC nationwide 02/24/21 CRL makes first at-home COVID-19 saliva test available through Walgreens 02/23/21 Walgreens launches rollout of same-day delivery with Instacart 02/19/21 Walgreens provides over 3M COVID-19 vaccinations 02/03/21 Capri Holdings sees lower Q4 revenue than previously expected 01/07/21 Capri Holdings to replace Enphase Energy in the S&P 400 at open on January 7 01/06/21 Celsius Holdings confirms addition to S&P SmallCap 600 Index, effective Jan. 7 02/04/21 Capri Holdings price target raised to $52 from $50 at Barclays 01/29/21 Baird Capri upgraded to Outperform on multi-year recovery at Baird 01/29/21 Baird Capri Holdings upgraded to Outperform from Neutral at Baird 01/27/21 Citi Capri Holdings price target raised to $53 from $32 at Citi WBA Walgreens Boots Alliance 01/27/21 Deutsche Bank Walgreens Boots Alliance price target raised to $49 from $44 at Deutsche Bank 01/15/21 Baird Walgreens Boots Alliance price target raised to $64 from $55 at Baird 01/11/21 Fly Intel: Top five analyst upgrades 01/11/21 Baird Baird upgrades Walgreens Boots Alliance following Q1 results WBA Walgreens Boots Alliance 01/07/21 Walgreens Boots Alliance backs FY21 adjusted EPS view up low single digits 01/07/21 Walgreens Boots Alliance reports Q1 adjusted EPS $1.22, consensus $1.03 01/06/21 Notable companies reporting before tomorrow's open 02/03/21 Capri Holdings reports Q3 adjusted EPS $1.65, consensus $1.01 11/05/20 Capri Holdings sees Q3 sales down double digits, consensus $1.27B 11/05/20 Capri Holdings sees FY sales down approximately 30%, consensus $3.79B 11/05/20 Capri Holdings not providing earnings guidance for FY21 WBA Walgreens Boots Alliance 02/14/21 Walmart COVID vaccine rollout heading to small towns, WSJ reports 01/26/21 Walgreens Boots Alliance set to name Starbucks COO Roz Brewer as CEO, WSJ says 01/26/21 Walgreens to name Starbucks executive Roz Brewer as CEO, WSJ says 12/20/20 CDC panel says frontline workers, people over 74 should be next, NYTimes reports 10/26/20 Hedgeye adds Capri Holdings to best ideas list, Bloomberg says WBA Walgreens Boots Alliance 01/27/21 Fly Intel: Wall Street's top stories for Wednesday 01/27/21 Fly Intel: Wall Street's top stories at midday 01/26/21 Fly Intel: After-Hours Movers 01/11/21 Zillow, Walgreens upgrades among today's top calls on Wall Street 12/31/20 Fly Intel: Pre-market Movers 12/30/20 Fly Intel: After-Hours Movers 11/20/20 Nikola initiation at Loop among today's top calls on Wall Street 11/17/20 American initiation, Moderna downgrade among today's top calls on Wall Street WBA Walgreens Boots Alliance 02/09/21 Walgreen Boots call volume above normal and directionally bullish 01/29/21 Walgreen Boots call volume above normal and directionally bullish 01/11/21 Early notable gainers among liquid option names on January 11th 12/31/20 Walgreen Boots call volume above normal and directionally bullish 02/10/21 Capri Holdings put volume heavy and directionally bearish 02/08/21 Capri Holdings put volume heavy and directionally bearish 01/29/21 Capri Holdings put volume heavy and directionally bearish 01/27/21 Capri Holdings put volume heavy and directionally bearish
Conference/Events
2021 London Global…
2021 London Global Healthcare Virtual Conference will be held on March 2-4. Webcast Link
Show Hide Related Items >> <<
12/15/20 Zealand Pharma: Dasiglucagon did not meet primary endpoint in Phase 3 trial 12/15/20 Zealand Pharma announces data from Phase 3 dasiglucagon in CHI trial 11/20/20 Zealand Pharma increases share capital following exercise of employee warrants TAK Takeda Pharmaceutical 02/26/21 Novavax, Takeda finalize license agreement for COVID-19 vaccine in Japan 02/26/21 Takeda to divest type 2 diabetes portfolio to Teijin Pharma for JPY 133B 02/24/21 Takeda provides update on Novavax, Moderna COVID-19 vaccine candidates in Japan 02/12/21 Takeda Pharmaceutical's maribavir Phase 3 clinical trial met primary endpoint 02/22/21 Regeneron announces third FDA approval for PD-1 inhibitor Libtayo 02/12/21 Sanofi offers to acquire Kiadis Pharma shares for EUR 5.45 per share in cash 02/12/21 Regeneron, Sanofi announce results from Libtayo comparative study published 08:16 Today Acutus Medical appoints Duane Wilder as CCO 08:11 Today Philips partners with DiA Imaging Analysis to enhance ultrasound 05:19 Today Philips appoints Shez Partovi chief innovation and strategy officer 02/18/21 ClearPoint Neuro, Philips enter license and research agreement for Maestro 03/01/21 Homology Medicines regains worldwide rights to ophthalmology program 02/17/21 Novartis announces SCD grant agreement with Bill & Melinda Gates Foundation 02/16/21 Novartis reports Entresto granted expanded indication in chronic heart failure 02/11/21 Novartis' Sandoz agrees to acquire GSK's cephalosporin antibiotics business 01/19/21 NOV Inc. falls -6.5% 12/21/20 National Oilwell to adopt new corporate name 'NOV Inc.' 11/18/20 National Oilwell, NexTier Oilfield partner on field test of electric frac system 03/01/21 Lantheus announces publication of PyL results from pivotal studies 01/12/21 Lantheus announces submission of DMF for NM-01 in the U.S. 12/09/20 Lantheus reports acceptance, priority review of New Drug Application for PyLTM 12/09/20 Lantheus enters strategic collaboration with Point Biopharma to use PET 01/05/21 Inventiva announces Phase 3 lanifibranor trial details 12/07/20 Inventiva announces journal publication on effect of lanifibranor in ACLD 11/10/20 Inventiva announces conclusions from phase II meeting with FDA 11/06/20 Inventiva CMO Marie-Paule Richard to retire, Michael Cooreman to succeed 07:32 Today Fusion Pharmaceuticals to acquire Ipsen's IP, assets related to IPN-1087 02/26/21 Exelixis: Ipsen receives positive CHMP opinion for CABOMETYX/OPDIVO combo 02/22/21 Ipsen to announce new data from CLARINET FORTE study at ENETS Conference 11/30/20 Ipsen announces Fast Track designation for irinotecan liposome injection 08:04 Today Cipla receives final approval for generic version of GlaxoSmithKline's IMITREX 02/24/21 J&J's Janssen announces submission of sNDA to FDA for expanded Cabenuva use 02/24/21 ViiV Healthcare submits sNDA to FDA for HIV treatment Cabenuva 02/22/21 Sanofi, GSK initiate Phase 2 study of COVID-19 vaccine candidate $10.81 / +0.5301 (+5.16%)
01/08/21 Galecto appoints Anne Prener to board of directors 11/30/20 Galecto announces publication of GB0139 Phase 2a IPF results 02/10/21 Galapagos, Gilead discontinue Phase 3 ISABELA trials 02/10/21 Gilead, Galapagos discontinue ISABELA Phase 3 trials in IPF 01/21/21 Galapagos announces NICE recommendation for Jyseleca on NHS 12/15/20 Galapagos to assume development, manufacturing, other rights for Jyseleca 02/10/21 Model N discloses J&J agreed to transition to its Revenue Cloud for Life Science 01/19/21 CytoSorb approved in Korea for all EU approved indications 02/05/21 CureVac enters pact with UK Government to develop SARS-CoV-2 variant vaccine 02/04/21 CureVac expands CV8102 cancer program to advanced melanoma 02/03/21 CureVac, GSK in pact to jointly develop mRNA vaccines for COVID-19 01/07/21 Bayer signs collaboration, services agreement with CureVac for COVID-19 vaccine $148.03 / +2.725 (+1.88%)
02/12/21 Carlisle names Kelly P. Kamienski as Controller 02/02/21 Carlisle announces additional buyback of 5M shares of common stock 02/25/21 Pfizer, BioNTech to evaluate safety of third dose of COVID-19 vaccine 02/22/21 Amyris announces pre-clinical results for COVID RNA vaccine platform 02/19/21 Pfizer, BioNTech submit COVID-19 vaccine stability data to the FDA 02/18/21 Pfizer, BioNTech start trial to evaluate COVID-19 vaccine in pregnant women 07:25 Today AstraZeneca advances mass global rollout of COVID-19 vaccine through COVAX 03/01/21 FibroGen, AstraZeneca report FDA to hold AdCom meeting to review roxadustat NDA 02/26/21 Amgen, AstraZeneca report 'positive' results from NAVIGATOR Phase 3 trial 02/24/21 ChemoCentryx appoints Tausif Butt as EVP, COO 02/24/21 Amedisys promotes Christopher Gerard to COO, Scott Ginn to CFO 01/05/21 Amedisys, Option Care Health collaborate on COVID therapy access model 12/23/20 Amedisys announces up to $100M share repurchase plan 02/08/21 Point72 Asset Management reports 5.0% passive stake in Affimed N.V. 02/03/21 Affimed N.V. announces pact with Roche to study AFM24/atezolizumab combo 01/07/21 Affimed N.V. provides pipeline and business update 11/19/20 Affimed announces publication of results from study of ICE with Keytruda 01/06/21 AmerisourceBergen to acquire Alliance Healthcare from Walgreens for $6.5B 11/09/20 AmerisourceBergen names Dr. Lonie Haynes as Chief Diversity & Inclusion Office 11/06/20 AmerisourceBergen reaches agreement with CDC over pharmacy vaccine access 11/05/20 AmerisourceBergen sees FY21 CapEx ~$400M 02/09/21 Mizuho AmerisourceBergen price target raised to $114 from $104 at Mizuho 02/08/21 Cowen AmerisourceBergen price target raised to $150 from $145 at Cowen 02/04/21 Evercore ISI AmerisourceBergen upgraded to Outperform after Q1 report at Evercore ISI 02/04/21 Evercore ISI AmerisourceBergen upgraded to Outperform from In Line at Evercore ISI 02/23/21 Benchmark Amedisys price target raised to $325 from $275 at Benchmark 02/08/21 Deutsche Bank Amedisys price target raised to $340 from $275 at Deutsche Bank 01/05/21 Truist Amedisys price target raised to $325 from $280 at Truist 11/03/20 Barclays Amedisys price target raised to $298 from $290 at Barclays 02/25/21 Fly Intel: Top five analyst upgrades 02/25/21 UBS AstraZeneca upgraded to Buy from Neutral at UBS 02/04/21 Piper Sandler Alexion downgraded to Neutral ahead of expected deal closing at Piper Sandler 02/01/21 BofA BofA downgrades Moderna to Underperform, sees shares priced for 'best-case' 02/23/21 B. Riley Securities B. Riley remains 'aggressive' buyer of Novavax after updated FDA guidance 02/01/21 SVB Leerink Moderna price target raised to $80 from $69 at SVB Leerink 01/29/21 Piper Sandler Moderna, Pfizer keep Covid vaccine competitive advantage, says Piper Sandler 01/14/21 Morgan Stanley 80%+ efficacy from J&J vaccine would be 'compelling,' says Morgan Stanley $148.03 / +2.725 (+1.88%)
01/26/21 Longbow Carlisle price target raised to $160 from $150 at Longbow 01/08/21 Oppenheimer Carlisle price target raised to $175 from $160 at Oppenheimer 11/13/20 Carlisle cut to Hold at Loop Capital on valuation 11/13/20 Loop Capital Carlisle downgraded to Hold from Buy at Loop Capital 01/07/21 Morgan Stanley CureVac COVID-19 deal provides 'sentiment boost' for Bayer, says Morgan Stanley 12/10/20 Credit Suisse CureVac downgraded to Underperform on rising valuation at Credit Suisse 12/10/20 Credit Suisse CureVac downgraded to Underperform from Neutral at Credit Suisse 11/02/20 Piper Sandler CureVac's positive vaccine data bodes well for Arcturus's ARCT-021, says Piper 02/26/21 JPMorgan Fresenius Medical price target raised to EUR 52.40 from EUR 51.10 at JPMorgan 02/24/21 Truist Fresenius Medical cut to Hold at Truist on more difficult operating backdrop 02/24/21 Truist Fresenius Medical downgraded to Hold from Buy at Truist 02/17/21 UBS Fresenius Medical price target lowered to EUR 72 from EUR 94 at UBS 02/23/21 BofA Galapagos upgraded to Neutral from Underperform at BofA 02/23/21 BofA Galapagos upgraded to Neutral from Underperform at BofA 02/19/21 Raymond James Raymond James upgrades 'heavily discounted' Galapagos to Outperform 02/19/21 Raymond James Galapagos upgraded to Outperform from Market Perform at Raymond James $10.81 / +0.5301 (+5.16%)
11/23/20 SVB Leerink SVB Leerink bullish on Galecto, initiates with an Outperform 11/23/20 SVB Leerink Galecto initiated with an Outperform at SVB Leerink 11/23/20 Credit Suisse Galecto initiated with an Outperform at Credit Suisse 11/23/20 BofA Galecto initiated with a Buy at BofA 02/12/21 Morgan Stanley GlaxoSmithKline price target lowered to 1,580 GBp at Morgan Stanley 02/11/21 Berenberg GlaxoSmithKline price target lowered to 1,570 GBp from 1,720 GBp at Berenberg 02/09/21 JPMorgan GlaxoSmithKline price target lowered to 1,300 GBp from 1,500 GBp at JPMorgan 02/08/21 UBS GlaxoSmithKline price target lowered to 1,320 GBp from 1,450 GBp at UBS 10/13/20 Roth Capital Roth backs Buy on Inventiva after Lanifibranor given breakthrough designation 08/17/20 H.C. Wainwright Inventiva price target raised to $38 from EUR 12 at H.C. Wainwright 08/05/20 Fly Intel: Top five analyst initiations 08/05/20 Roth Capital Inventiva initiated with a Buy at Roth Capital 02/16/21 Barclays Ipsen price target lowered to EUR 89 from EUR 96 at Barclays 01/14/21 Societe Generale Ipsen upgraded to Buy from Hold at Societe Generale 12/08/20 Morgan Stanley Ipsen downgraded to Equal Weight from Overweight at Morgan Stanley 12/04/20 BofA Ipsen downgraded to Neutral from Buy at BofA 02/01/21 Fly Intel: Top five analyst initiations 02/01/21 SVB Leerink SVB Leerink bullish on Lantheus, initiates with an Outperform 02/01/21 SVB Leerink Lantheus initiated with an Outperform at SVB Leerink 12/29/20 Credit Suisse Lantheus price target lowered to $14 from $16 at Credit Suisse 01/21/21 Susquehanna NOV Inc. price target lowered to $17 from $18 at Susquehanna 01/21/21 Wells Fargo NOV Inc. upgraded to Overweight from Equal Weight at Wells Fargo 01/21/21 Wells Fargo NOV Inc. upgraded to Overweight from Equal Weight at Wells Fargo 01/12/21 Citi NOV Inc. upgraded to Buy from Neutral at Citi 03/01/21 Oppenheimer Homology Medicines loses potential source of upside, says Oppenheimer 02/02/21 Morgan Stanley Novartis price target lowered to CHF 102 from CHF 104 at Morgan Stanley 02/01/21 Truist iRhythm price target lowered to $220 from $265 at Truist 02/01/21 Cowen Novartis downgraded to Market Perform after 'tepid' guidance at Cowen 01/26/21 Credit Suisse Philips price target raised to EUR 45 from EUR 41 at Credit Suisse 01/26/21 JPMorgan Philips price target raised to EUR 44.90 from EUR 44 at JPMorgan 01/26/21 UBS Philips price target raised to EUR 54 from EUR 51 at UBS 01/25/21 Morgan Stanley iRhythm price target raised to $288 from $227 at Morgan Stanley 02/23/21 BofA BofA adds Heineken and IAG, removes Roche and Sanofi from Europe 1 list 02/10/21 Morgan Stanley Sanofi price target raised to EUR 104 from EUR 101 at Morgan Stanley 02/05/21 Piper Sandler Piper reiterates Overweight on Kymera after Sanofi capital markets day 01/19/21 UBS Sanofi price target lowered to EUR 99 from EUR 100 at UBS TAK Takeda Pharmaceutical 01/29/21 Morgan Stanley Morgan Stanley downgrades Jazz to Equal Weight ahead of competitor readout 12/29/20 Needham Needham names Phathom Pharmaceuticals Top Pick for 2021 12/15/20 Needham Phathom Pharmaceuticals price target raised to $55 from $45 at Needham 06/18/20 RBC Capital Neurocrine price target raised to $135 from $116 at RBC Capital 03/10/20 Morgan Stanley Zealand Pharma EPS estimates cut at Morgan Stanley 11/12/20 Zealand Pharma expects 2020 revenue for V-Go sales DKK150M-DKK175M 11/12/20 Zealand Pharma reports Q3 revenue DKK56.5M vs. DKK9.9M last year 02/05/21 Sanofi reports Q4 business EPS EUR 1.22, flat vs. last year 10/29/20 Sanofi reports Q3 business EPS EUR 1.83, up 0.5% from last year 01/25/21 Philips reports Q4 adjusted EPS EUR 0.94 vs. EUR 0.83 last year 10/19/20 Philips reports Q3 adj. EPS EUR 0.60 vs. EUR 0.46 last year 01/26/21 Novartis sees 2021 core operating income to grow mid single digit 01/26/21 Novartis reports Q4 core EPS $1.34, consensus $1.36 11/05/20 Xoma reports Q3 EPS (10c), consensus (21c) 10/27/20 Novartis raises FY20 core operating income growth outlook 02/04/21 NOV Inc. reports Q4 EPS (90c), consensus (19c) 01/19/21 NOV lowers Q4 revenue view to $1.33B, consensus $1.36B 10/26/20 National Oilwell reports Q3 EPS (14c), consensus (10c) 02/25/21 Lantheus sees Q1 EPS (3c) to 0c, consensus 2c 02/25/21 Lantheus reports Q EPS 7c, consensus 1c 11/05/20 Lantheus reports Q3 adj. EPS 4c, consensus 1c 02/03/21 GlaxoSmithKline reports Q4 adjusted EPS 23.3p vs. 24.8p a year ago 10/28/20 GlaxoSmithKline now sees 2020 adjusted EPS at lower end of down 1%-4% range 10/28/20 GlaxoSmithKline reports Q3 adjusted EPS 35.6p vs. 38.6p a year ago 10/08/20 GlaxoSmithKline sees impact of foreign exchange on Q3 sales of about 5% $10.81 / +0.5301 (+5.16%)
12/11/20 Galecto reports Q3 EPS ($55.25) vs. ($21.18) last year 02/18/21 Galapagos reports FY 20 EUR 530M versus EUR 886M in 2019 $148.03 / +2.725 (+1.88%)
02/04/21 Carlisle reports Q4 EPS $1.57, consensus $1.16 10/20/20 Carlisle reports Q3 EPS $1.87, consensus $1.68 02/11/21 AstraZeneca sees FY21 core EPS $4.75-$5.00 02/11/21 AstraZeneca reports Q4 core EPS $1.07, total revenue $7.41B 11/05/20 AstraZeneca backs view for FY20 core EPS up by a mid- to high-teens percentage 11/05/20 AstraZeneca reports Q3 core EPS 94c, down 4% year-over-year 02/24/21 Amedisys sees FY21 adjusted EPS $6.25-$6.47, consensus $6.31 02/24/21 Amedisys reports Q4 adjusted EPS $1.49, consensus $1.47 10/28/20 Amedisys sees FY20 EPS $6.02- $6.08, consensus $4.98 10/28/20 Amedisys reports Q3 EPS $2.24, consensus $1.28 02/04/21 AmerisourceBergen raises FY21 adjusted EPS view to $8.40-$8.60 from $8.25-$8.50 02/04/21 AmerisourceBergen reports Q1 adjusted EPS $2.18, consensus $1.94 02/03/21 Notable companies reporting before tomorrow's open
Periodicals
President Biden will…
President Biden will announce today that Merck (MRK) will help make Johnson & Johnson's (JNJ) single-shot coronavirus vaccine, Laurie McGinley and Christopher Rowland of Washington Post report, citing senior administration officials. Under the arrangement, Merck will dedicate two facilities in the United States to Johnson & Johnson's shots, officials told the paper. Reference Link
Show Hide Related Items >> <<
03/01/21 Merck announces voluntary withdrawal for KEYTRUDA in SCLC 03/01/21 Merck: FDA accepts gefapixant New Drug Application for review 02/25/21 Merck to acquire Pandion Therapeutics for $60 per share in cash 02/25/21 Merck, Pandion Therapeutics deal has approx. total equity value of $1.85B 02/28/21 Fly Intel: Top five weekend stock stories 02/28/21 CDC Advisory Committee recommends J&J single-shot COVID vaccine for adults 18+ 02/27/21 Johnson & Johnson Covid vaccine granted emergency approval from FDA 02/26/21 J&J confirms FDA panel recommends COVID-19 vaccine for EUA 02/25/21 SVB Leerink Pandion Therapeutics downgraded to Market Perform from Outperform at SVB Leerink 02/25/21 Morgan Stanley Pandion downgraded to Equal Weight from Overweight at Morgan Stanley 02/17/21 William Blair William Blair 'highly encouraged' by Nektar's collaborations with Merk, SFJ 01/21/21 Wedbush Scholar Rock price target raised to $66 from $47 at Wedbush 02/10/21 BTIG Model N upgraded to Buy from Neutral at BTIG 02/01/21 SVB Leerink Moderna price target raised to $80 from $69 at SVB Leerink 02/01/21 Wells Fargo Moderna price target raised to $145 from $129 at Wells Fargo 02/01/21 BofA BofA downgrades Moderna to Underperform, sees shares priced for 'best-case' 02/04/21 Merck sees FY21 adjusted EPS $6.48-$6.68, consensus $6.41 02/04/21 Merck reports Q4 adjusted EPS $1.32, consensus $1.38 02/03/21 Notable companies reporting before tomorrow's open 01/26/21 Johnson & Johnson sees FY21 adjusted operational EPS $9.25-$9.45 01/26/21 Johnson & Johnson reports Q4 adjusted EPS $1.86, consensus $1.82 01/25/21 Notable companies reporting before tomorrow's open 02/10/21 Merck in talks to produce authorized COVID-19 vaccines, WSJ says 02/03/21 Records show Merck's Propecia has trail of suicide reports, Reuters says 12/23/20 Judge rules against White House drug pricing rule, Reuters says 12/19/20 Alphabet, Apple among Barron's 10 Top stocks for 2021, Barron's says 06:20 Today Johnson & Johnson Covid-19 vaccine shipments begin rollout, WSJ reports 02/26/21 FDA panel says J&J COVID-19 vaccine benefits outweigh risks, CNBC says 02/26/21 FDA advisory panel to review J&J's Covid-19 vaccine Friday, WSJ reports 02/25/21 Johnson & Johnson one-dose COVID-19 vaccine approved by Bahrain, Reuters says 02/25/21 Fly Intel: Wall Street's top stories for Thursday 02/25/21 Fly Intel: Wall Street's top stories at midday 02/25/21 Fly Intel: Pre-market Movers 02/04/21 Fly Intel: Wall Street's top stories for Thursday 03/01/21 Fly Intel: Wall Street's top stories for Monday 03/01/21 Fly Intel: Wall Street's top stories at midday 03/01/21 Fly Intel: Pre-market Movers 02/24/21 Fly Intel: Wall Street's top stories for Wednesday 02/17/21 Merck call volume above normal and directionally bullish 12/23/20 Merck call volume above normal and directionally bullish 10/20/20 Merck put volume heavy and directionally bearish 03/01/21 Unusually active option classes on open March 1st 01/26/21 Early notable gainers among liquid option names on January 26th 12/01/20 Johnson & Johnson call volume above normal and directionally bullish 10/13/20 Unusually active option classes on open October 13th
Recommendations
Cowen analyst Charles…
Cowen analyst Charles Ryhee raised the firm's price target on McKesson to $224 from $210 and keeps an Outperform rating on the shares. The analyst raised his target as he is incrementally positive on the company given its suite of differentiated assets in oncology biopharma services an med-surg which are expected to be key growth drivers going forward.
Show Hide Related Items >> <<
03/01/21 FedEx begins shipping newly approved Covid vaccine on behalf of McKesson 12/20/20 Fly Intel: Top five weekend stock stories 12/20/20 FedEx to ship first wave of Moderna COVID-19 vaccines across the U.S. 12/04/20 McKesson, Amgen sign strategic agreement to help improve cancer care 02/03/21 Credit Suisse McKesson price target raised to $192 from $178 at Credit Suisse 02/03/21 Deutsche Bank McKesson price target raised to $231 from $222 at Deutsche Bank 02/03/21 Mizuho McKesson price target raised to $190 from $178 at Mizuho 02/01/21 Cowen McKesson price target raised to $210 from $186 at Cowen 02/02/21 McKesson raises FY21 adjusted EPS view to $16.95-$17.25 from $16.00-$16.50 02/02/21 McKesson reports Q3 adjusted EPS $4.60, consensus $4.13 02/01/21 Notable companies reporting before tomorrow's open 06:20 Today Johnson & Johnson Covid-19 vaccine shipments begin rollout, WSJ reports 02/16/21 McKesson in talks to sell LloydsPharmacy chain, Sky News reports 01/20/21 McKesson to replace some Moderna vaccine shots shipped too cold, Bloomberg says 11/05/20 Distributors and J&J closing in on $26B opioid settlement deal, NY Times says 02/02/21 Fly Intel: Wall Street's top stories for Tuesday 02/02/21 Fly Intel: Wall Street's top stories at midday 02/02/21 Fly Intel: Pre-market Movers 11/24/20 Fly Intel: Wall Street's top stories at midday 11/03/20 Early notable gainers among liquid option names on November 3rd
Yesterday
On The Fly
The three major averages…
Show Hide Related Items >> <<
03/01/21 Michael Angelakis and Jeffrey Ubben join ExxonMobil board 02/24/21 Exxon Mobil to sell U.K. upstream central and northern North Sea assets 02/16/21 Paulson & Co. buys Exxon, exits Qiagen in Q4 02/12/21 Exxon Mobil targets cash operating expense reduction of $6B by FY23 $31.62 / -27.515 (-46.53%)
10/29/20 Ontrak acquires behavior change platform LifeDojo 10/13/20 Ontrak rises after announcing launch of Ontrak-CI program $84.57 / +48.64 (+135.37%)
03/01/21 Morphic Holding Inc trading resumes 03/01/21 Morphic Holding Inc trading halted, volatility trading pause 03/01/21 Morphic Holding reports interim results from Phase 1 trial of MORF-057 01/05/21 Morphic Therapeutic expands R&D collaboration with Janssen 02/28/21 Fly Intel: Top five weekend stock stories 02/28/21 CDC Advisory Committee recommends J&J single-shot COVID vaccine for adults 18+ 02/27/21 Johnson & Johnson Covid vaccine granted emergency approval from FDA 02/26/21 J&J confirms FDA panel recommends COVID-19 vaccine for EUA 02/26/21 DraftKings MUPs for B2C segment up 44% vs. 4Q19 02/25/21 Bill introduced in Florida Senate to authorize sports wagering 02/25/21 Nevada reports January statewide gaming win down 26.6% to $761.85M 02/25/21 DraftKings names Cal Ripken Jr. as special advisor to board of directors 03/01/21 Athenex trading resumes 03/01/21 Athenex expects cash to fund operations into 2Q22 03/01/21 Athenex announces key anticipated future milestones 03/01/21 FDA requests new study from Athenex for oral paclitaxel plus encequidar 02/10/21 BTIG Model N upgraded to Buy from Neutral at BTIG 02/01/21 SVB Leerink Moderna price target raised to $80 from $69 at SVB Leerink 02/01/21 Wells Fargo Moderna price target raised to $145 from $129 at Wells Fargo 02/01/21 BofA BofA downgrades Moderna to Underperform, sees shares priced for 'best-case' 07:00 Today Wells Fargo Exxon Mobil price target raised to $65 from $53 at Wells Fargo 02/26/21 Barclays Exxon Mobil price target raised to $65 from $59 at Barclays 02/16/21 Credit Suisse Exxon Mobil price target raised to $62 from $52 at Credit Suisse 02/08/21 Fly Intel: Top five analyst upgrades $31.62 / -27.515 (-46.53%)
08:36 Today B. Riley Securities Ontrak price target lowered to $73 from $110 at B. Riley Securities 07:39 Today Cowen Cowen downgrades Ontrak to Market Perform until visibility returns 07:28 Today Canaccord Canaccord downgrades Ontrak after loss of largest customer 05:57 Today Cowen Ontrak downgraded to Market Perform from Outperform at Cowen 08:31 Today SVB Leerink Athenex downgraded to Market Perform from Outperform at SVB Leerink 07:27 Today Oppenheimer Athenex downgraded to Perform from Outperform at Oppenheimer 07:13 Today Truist Athenex downgraded to Hold from Buy at Truist 06:39 Today RBC Capital Athenex price target lowered to $9 from $33 at RBC Capital 03/01/21 Craig-Hallum DraftKings price target raised to $70 from $65 at Craig-Hallum 03/01/21 Canaccord DraftKings price target raised to $80 from $65 at Canaccord 03/01/21 Northland DraftKings price target raised to $70 from $55 at Northland 03/01/21 Benchmark DraftKings price target raised to $69 from $66 at Benchmark $84.57 / +48.64 (+135.37%)
03/01/21 Wells Fargo Morphic Holding price target raised to $103 from $40 at Wells Fargo 02/02/21 RBC Capital Morphic Holding price target raised to $50 from $35 at RBC Capital 10/26/20 RBC Capital Morphic Holding initiated with an Outperform at RBC Capital 08/11/20 BMO Capital Morphic Holding price target raised to $37 from $30 at BMO Capital 02/02/21 Exxon Mobil reports Q4 ex-items EPS 3c, consensus 1c 02/01/21 Notable companies reporting before tomorrow's open 12/30/20 Exxon Mobil says Q4 income boosted by up to $600M from gas prices $31.62 / -27.515 (-46.53%)
03/01/21 Ontrak sees FY21 revenue $100M, consensus $165.05M 03/01/21 Ontrak reports Q4 EPS (7c), consensus (30c) 11/05/20 Ontrak reports Q3 EPS (36c), consensus (35c) $84.57 / +48.64 (+135.37%)
03/01/21 Morphic Holding reports 2020 EPS ($1.47), consensus ($1.41) 11/09/20 Morphic Holding reports Q3 EPS 17c, consensus (48c) 01/26/21 Johnson & Johnson sees FY21 adjusted operational EPS $9.25-$9.45 01/26/21 Johnson & Johnson reports Q4 adjusted EPS $1.86, consensus $1.82 01/25/21 Notable companies reporting before tomorrow's open 02/26/21 DraftKings raises 2021 revenue view to $900M-$1B from $750M-$850M 02/26/21 DraftKings reports Q4 revenue $322M, consensus $232.6M 02/25/21 Notable companies reporting before tomorrow's open 03/01/21 Athenex reports Q4 adjusted EPS (43c), consensus (44c) 11/05/20 Athenex sees 2020 y-o-y product sales growth in low twenties percentage growth 11/05/20 Athenex reports Q3 EPS (44c), consensus (43c)
Conference/Events
Biopharmaceuticals…
Biopharmaceuticals Analyst Chen, along with Dr. Ruchita Amin, Retina Specialist at Retina Vitreous Associates and Dr. Roger Goldberg, Partner and Vitreoretinal Surgeon at Bay Area Retina Associates, discuss hot topics and key 2021 focus areas in eye diseases on an Analyst/Industry Conference Call to be held on March 8 at 1 pm.
Show Hide Related Items >> <<
02/24/21 Unity Biotechnology reports granting of employment inducement awards 02/08/21 Unity Biotechnology's UBX1325 shows eye disease treatment potential in study 02/03/21 Unity Biotechnology reports granting of employment inducement awards 02/01/21 Unity Biotechnology appoints Mike Sapieha as Chief Scientific Advisor 01/26/21 MeiraGTx granted fast track designation for AAV-CNGA3 11/13/20 MeiraGTx gene therapy demonstrates improvement in XLRP 10/04/20 MeiraGTx announces 9-month data from Phase 1/2 Trial of AAV-RPGR 02/28/21 Fly Intel: Top five weekend stock stories 02/28/21 CDC Advisory Committee recommends J&J single-shot COVID vaccine for adults 18+ 02/27/21 Johnson & Johnson Covid vaccine granted emergency approval from FDA 02/26/21 J&J confirms FDA panel recommends COVID-19 vaccine for EUA 02/03/21 Biogen sees FY21 adjusted R&D expense $2.35B-$2.45B 02/03/21 Biogen CEO sees 'a financial reset in 2021' 02/01/21 Biogen announces FDA approval of PLEGRIDY intramuscular administration 01/29/21 Biogen, Eisai announce 3-month extension of review period for aducanumab BLA 02/04/21 Aldeyra announces Phase 3 TRANQUILITY dry eye disease trial design 01/21/21 Aldeyra rises 6% after 1.37M share purchase disclosed by Perceptive Advisors 01/07/21 Aldeyra announces top-line results from run-in cohort in Tranquility study 12/22/20 Aldeyra confirms SARS-CoV-2 antiviral activity of ADX-1612 02/11/21 Applied Genetic expects cash, cash equivalents to fund programs into 2023 11/11/20 Applied Genetic reports additional data from Phase 1/2 trial in XLRP 10/07/20 Applied Genetic joins My Retina Tracker program as scientific collaborator 09/09/20 Applied Genetic on track for data readouts for ACHM program in Q4 AERI Aerie Pharmaceuticals 01/11/21 Aerie Pharmaceuticals receives EC marketing approval for Roclanda 11/13/20 Aerie Pharmaceuticals' Roclanda receives positive CHMP opinion in the EU 10/29/20 Aerie Pharmaceuticals initiates Phase 2b trial AR-15512 10/28/20 Aerie, Santen enter exclusive agreement for Rhopressa and Rocklatan in Japan ADVM Adverum Biotechnologies 02/22/21 Adverum appoints Reed Tuckson to board of directors 02/02/21 Adverum announces publication of safety data on ADVM-022 gene therapy 01/11/21 Adverum Biotechnologies announces 2021 focus areas 01/11/21 Adverum Biotechnologies completes patient enrollment for INFINITY Phase 2 trial ADVM Adverum Biotechnologies 12/15/20 UBS Adverum Biotechnologies initiated with a Neutral at UBS 11/15/20 Piper Sandler Adverum Biotechnologies shares should grind higher over time, says Piper Sandler 11/12/20 Raymond James Adverum Biotechnologies upgraded to Market Perform from Underperform at Raymond James 11/12/20 Raymond James Adverum Biotechnologies upgraded to Market Perform at Raymond James 02/16/21 Citi Unity Biotechnology downgraded to Sell from Neutral at Citi 08/18/20 Fly Intel: Top five analyst downgrades 08/18/20 Morgan Stanley Unity Biotechnology downgraded at Morgan Stanley as UBX101 doesn't meet endpoint 08/18/20 Citi Unity Biotechnology downgraded to Neutral from Buy at Citi 02/02/21 H.C. Wainwright Applied Genetic price target raised to $24 from $18 at H.C. Wainwright 02/01/21 Roth Capital Applied Genetic price target raised to $35 from $30 at Roth Capital 11/17/20 Roth Capital Applied Genetic price target raised to $30 from $26 at Roth Capital 11/11/20 H.C. Wainwright Applied Genetic XLRP data 'continue to impress,' says H.C. Wainwright 02/10/21 BTIG Model N upgraded to Buy from Neutral at BTIG 02/01/21 SVB Leerink Moderna price target raised to $80 from $69 at SVB Leerink 02/01/21 Wells Fargo Moderna price target raised to $145 from $129 at Wells Fargo 02/01/21 BofA BofA downgrades Moderna to Underperform, sees shares priced for 'best-case' 02/16/21 Chardan MeiraGTx called a Top Pick for 2021 at Chardan 12/17/20 Chardan Chardan boosts MeiraGTx target to $55, say buy shares 'now' 12/17/20 Piper Sandler Piper says MeiraGTx not getting credit for RIX gene therapy that 'clearly works' 10/22/20 RBC Capital MeiraGTx initiated with an Outperform at RBC Capital NITE Nightstar Therapeutics 02/17/21 Cantor Fitzgerald Biogen price target lowered to $268 from $278 at Cantor Fitzgerald 02/08/21 Citi Expert sees Biogen aducanumab approval 50/50 at best, says Citi 02/04/21 SVB Leerink Biogen price target lowered to $380 from $430 at SVB Leerink 02/04/21 Credit Suisse Biogen price target lowered to $338 from $350 at Credit Suisse AERI Aerie Pharmaceuticals 11/09/20 H.C. Wainwright Aerie Pharmaceuticals price target lowered to $29 from $31 at H.C. Wainwright 10/28/20 H.C. Wainwright Aerie Pharmaceuticals $50M upfront should reduce overhang, says H.C. Wainwright 10/19/20 BofA Aerie Pharmaceuticals downgraded to Underperform from Neutral at BofA 10/19/20 BofA Aerie Pharmaceuticals downgraded to Underperform from Neutral at BofA 02/08/21 H.C. Wainwright Aldeyra initiated with a Buy at H.C. Wainwright 01/28/21 JonesTrading Aldeyra assumed with a Buy at JonesTrading 01/08/21 Jefferies Aldeyra could double if topline of TRANQUILITY study positive, says Jefferies 01/08/21 Citi Aldeyra shares have 'plenty of upside' despite 26% rally, says Citi 11/04/20 Unity Biotechnology reports Q3 EPS (52c), consensus (49c) 11/05/20 MeiraGTx reports Q3 EPS (17c), consensus (70c) 10/28/20 MeiraGTx to present data on phase 1/2 clinical trial on AAV-RPGR 01/26/21 Johnson & Johnson sees FY21 adjusted operational EPS $9.25-$9.45 01/26/21 Johnson & Johnson reports Q4 adjusted EPS $1.86, consensus $1.82 01/25/21 Notable companies reporting before tomorrow's open 02/03/21 Biogen sees FY21 adjusted EPS $17.00-$18.50, consensus $24.67 02/03/21 Biogen reports Q4 adjusted EPS $4.58, consensus $4.87 02/02/21 Notable companies reporting before tomorrow's open 11/05/20 Aldeyra reports Q3 EPS (23c), consensus (27c) 02/11/21 Applied Genetic reports Q4 EPS (60c), consensus (59c) 11/16/20 Applied Genetic reports Q4 EPS (60c), consensus (53c) 09/09/20 Applied Genetic reports Q4 EPS (56c), consensus (48c) AERI Aerie Pharmaceuticals 02/25/21 Aerie Pharmaceuticals reports Q4 EPS (79c), consensus (73c) 11/05/20 Aerie Pharmaceuticals reports Q3 EPS (86c), consensus (80c) ADVM Adverum Biotechnologies 11/05/20 Adverum Biotechnologies reports Q3 EPS (31c), consensus (34c)